Technical Analysis for KALA - Kala Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 6.315 1.20% 0.08
KALA closed up 0.65 percent on Tuesday, January 15, 2019, on 79 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical KALA trend table...

Date Alert Name Type % Chg
Jan 15 50 DMA Support Bullish 1.20%
Jan 15 NR7 Range Contraction 1.20%
Jan 15 Inside Day Range Contraction 1.20%
Jan 15 Wide Bands Range Expansion 1.20%
Jan 15 Overbought Stochastic Strength 1.20%
Jan 15 Up 3 Days in a Row Strength 1.20%
Jan 14 50 DMA Support Bullish 1.85%
Jan 14 Wide Bands Range Expansion 1.85%
Jan 14 Overbought Stochastic Strength 1.85%
Jan 11 Crossed Above 50 DMA Bullish 3.52%

Older signals for KALA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Is KALA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 7 Kala Pharmaceuticals launches INVELTYS
Jan 7 Kala Pharmaceuticals Announces the Launch of INVELTYS™ and the Hiring of a Specialty Ophthalmology Sales Organization
Jan 4 Kala Pharmaceuticals, Inc.’s (NASDAQ:KALA) Path To Profitability
Jan 2 Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Dec 28 Kala Pharmaceuticals: Update And 2019 Outlook
Dec 28 Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape
Dec 26 FDA accepts for review Kala Pharmaceuticals' NDA for KPI-121 0.25%
Dec 26 Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
Dec 21 The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
See more KALA news...
Indicators
Indicator Value
52 Week High 18.3
52 Week Low 4.03
Average Volume 203,783
200-Day Moving Average 11.2426
50-Day Moving Average 6.005
20-Day Moving Average 5.353
10-Day Moving Average 5.942
Average True Range 0.4432
ADX 27.88
+DI 22.3265
-DI 14.513
Chandelier Exit (Long, 3 ATRs ) 5.1604
Chandelier Exit (Short, 3 ATRs ) 5.3596
Upper Bollinger Band 6.6965
Lower Bollinger Band 4.0095
Percent B (%b) 0.83
BandWidth 50.196152
MACD Line 0.0882
MACD Signal Line -0.0992
MACD Histogram 0.1875
Fundamentals Value
Market Cap 151.18 Million
Num Shares 24.2 Million
EPS -32.85
Price-to-Earnings (P/E) Ratio -0.19
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.60
Resistance 3 (R3) 6.56 6.40 6.54
Resistance 2 (R2) 6.40 6.31 6.42 6.52
Resistance 1 (R1) 6.32 6.25 6.36 6.36 6.50
Pivot Point 6.16 6.16 6.18 6.18 6.16
Support 1 (S1) 6.08 6.07 6.12 6.12 5.98
Support 2 (S2) 5.92 6.01 5.94 5.96
Support 3 (S3) 5.84 5.92 5.94
Support 4 (S4) 5.88